Photo from Fabrice Andre/X
Jan 29, 2024, 14:13
Fabrice Andre: Academic clinical trials should be evaluated mainly based on their IMPACT on patients, not only on innovation
Fabrice Andre, Head of Research Division of Gustave Roussy, President Elect of the European Society for Medical Oncology, shared a post on X/Twitter:
“Thank you, The Lancet for taking this question seriously. Academic clinical trials should be evaluated mainly based on their IMPACT on patients, not only on innovation. Too many grant committees give too much weight to innovation vs impact, when it’s about funding clinical trials.”
Quoting The Lancet’s post:
“On our cover this week:
A Viewpoint on the need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology.”
View additional information.
Source: Fabrice Andre/X and The Lancet/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14